

Table of Contents

Title	Pages
Certificate & Declaration by the Candidate by the Supervisor.....	ii-iii
Copyright Transfer Certificate.....	iv
Acknowledgement.....	v
Contents.....	ix
List of Figures.....	xiv
List of Tables.....	xxi
Preface.....	xxiii
1 Introduction.....	1
1.1 Backgrounds.....	3
1.2 Selection criteria of material for biomedical application.....	6
1.3 Progression of biomaterials.....	7
1.4 Classification of Biomaterials.....	8
1.5 Role of Bioceramic Characteristics for their Applications.....	9
1.5.1 Bioactivity.....	9
1.5.2 Degradability.....	9
1.5.3 Physicochemical Properties.....	10
1.6 Basic concept of composites.....	10
1.7 Classification of composites.....	12
1.8 Objective.....	14
2 Literature Review.....	17
2.1 Introduction.....	19
2.2 Bioactive glass.....	19
2.2.1 Bioactive Compositions.....	20
2.2.2 Producing bioactive glasses by melt quenching.....	21
2.2.3 Producing bioactive glasses by sol-gel processing.....	22

2.2.4 Stimulating bone growth.....	24
2.3 Hydroxyapatite ceramic	26
2.4 Calcium zirconium silicate ceramic.....	31
2.4.1 Processing of Calcium Zirconium silicate ceramic	33
2.5 Zinc Oxide.....	34
3 Materials, Methodology and Characterization Techniques.....	39
3.1 Overview.....	41
3.1 Materials and Method	41
3.2.1 Zirconia substituted 1393 bioactive glass preparation.....	41
3.2.2 Hydroxyapatite bioceramic preparation.....	43
3.2.3 Calcium Zirconium Silicate (Baghdadite) bio ceramic	44
3.2.4 Zinc Oxide.....	44
3.2 Composite preparation	44
3.2.1 Granulation and pellet processing.....	46
3.3.2 Sintering.....	46
3.3 Materials Characterization techniques	46
3.4.1 Thermal analysis (TGA-DSC).....	46
3.4.2 Phase Formation and Crystal Structure Studies by XRD	48
3.4.3 Fourier Transform Infrared Spectroscopy (FTIR).....	50
3.4.4 Microstructure and Elemental Analysis.....	52
3.4 In vitro bioactivity studies.....	54
3.5 Degradation analysis	56
3.6 Determination of Compressive Strength.....	56
3.7 Measurement of Density	57
3.8 Biological Evaluation.....	58
3.8.1 Cell culture.....	59
3.8.2 Nuclear staining.....	60

3.9	Hemocompatibility	61
3.10	3.9 Anti-Bacterial Evaluation	62
4	Zirconia substituted 1393 bioactive glass Hydroxyapatite composite system	63
4.1	Introduction	65
4.2	Materials and method.....	66
4.2.1	Synthesis of bioglass.....	66
4.2.2	Hydroxyapatite synthesis	67
4.2.3	Biocomposite preparation	67
4.3	Characterization and test	68
4.4	Statistical Analysis:.....	69
4.5	Results and discussion.....	69
4.5.1	Simultaneous Thermal analysis (STA).....	69
4.5.2	Phase analysis.....	70
4.5.3	Transmittance FTIR analysis	73
4.6	In-vitro bioactivity analysis.....	76
4.6.1	pH analysis	80
4.7	Physical (density) and mechanical properties	81
4.8	Biocompatibility analysis.....	83
4.9	Conclusion.....	84
5	Calcium Zirconium Silicate (Baghdadite) Zinc Oxide composite system	85
5.1	Introduction	87
5.2	Materials and method.....	88
5.2.1	Synthesis of baghdadite/zinc oxide composite.....	88
5.3	Thermal analysis.....	89
5.4	Phase, structural, and microstructure analysis.....	89
5.5	In-vitro bioactivity and chemical analysis.....	89
5.6	Density and compressive strength	90

5.7	In-vitro blood compatibility	90
5.8	Apoptosis analysis	91
5.9	In-vitro antibacterial test	91
5.10	Statistical analysis	91
5.11	Results and discussion	91
5.11.1	Thermal analysis	91
5.12	Phase, structural, and microstructural analysis	92
5.13	In-vitro bioactivity analysis	99
5.14	Chemical analysis.....	106
5.15	Density.....	108
5.16	In vitro blood compatibility	109
5.17	Apoptosis analysis	111
5.18	Antibacterial test	112
5.19	Conclusions.....	113
6	Zirconia substituted 1393 bioactive glass Zinc Oxide composite system.....	115
6.1	Introduction	117
6.2	Materials and Method:	118
6.2.1	Preparation of substituted bioactive glass/ ZnO composites.....	118
6.2.2	Characterization of Composites	119
6.2.3	In-vitro bioactivity in SBF	119
6.2.4	In-vitro biocompatibility assay:.....	120
6.2.5	Statistical analysis:.....	120
6.3	Results and Discussion:.....	120
6.3.1	Characterization.....	120
6.3.2	In-vitro bioactivity in SBF	122
6.3.3	In-vitro biocompatibility of composites.....	123
6.4	Conclusion.....	124

7	Zirconia substitute 1393 bioactive glass baghdadite composite system	127
7.1	Introduction	129
7.2	Materials and methods	130
7.2.1	Preparation of substituted 1393 bioglass/ baghdadite composites	130
7.3	Characterization of composites.....	131
7.4	In-vitro bioactivity behaviour analysis.....	131
7.5	Density measurement	132
7.6	Results and discussion.....	132
7.7.1	Structural analysis of composites	132
7.7.2	In-vitro bioactivity analysis.....	133
7.7.3	pH analysis	134
7.7.4	Density measurement.....	135
7.7	Conclusion.....	135
8	Conclusion and Future Scope	137
8.1	Conclusion	139
8.2	Future perspectives	143
9	References	145

List of Figures

Figure 1.1 Progression of biomaterials (Ratner et al., 2013).-----	8
Figure 1.2 Classification of composite materials (Ibrahim et al., 2015) (Mishra et al., 2018). -----	12
Figure 2.1 Property changes of bioglass materials (Henao et al., 2019).-----	21
Figure 2.2 Schematic presentation of bioglass synthesis (a) melt method, (b) sol-gel method (Kaur et al.,2016)-----	24
Figure 2.3 formation of hydroxycarbonate apatite (HCA) on the bioactive glass surface. ---	25
Figure 2.4 Schematic representation of the dissolution behavior of silicate bioactive glasses in simulated body fluid (Henao et al., 2019).-----	26
Figure 2.5 Crystal structure of baghdadite along the a-axis (Jodati et al., 2020). -----	32
Figure 2.6 Baghdadite synthesis by sol-gel method (Sadeghzade et al., 2017). -----	34
Figure 3.1 DSC-TGA instrument.-----	48
Figure 3.2 Visualization of Bragg’s law.-----	49
Figure 3.3 Schematic representation of $\theta/2\theta$ diffraction in Bragg-Brentano geometry.-----	49
Figure 3.4 XRD instrument, Central Instrument Facility (CIF, IIT BHU). -----	50
Figure 3.5 Principle of FT-IR spectroscopy and experimental set-up for FTIR measurement facility.-----	52
Figure 4.1 (a) DSC and (b) TGA graphs of bioglass/hydroxyapatite composite before the sintering process-----	70
Figure 4.2 XRD of zirconia substituted bioglass (BG_H0) and hydroxyapatite (HA). -----	71
Figure 4.3 (a) XRD of composites heated at 600 °C and (b) at 1000 °C. -----	72
Figure 4.4 (a) Transmittance FTIR spectra of zirconia substituted bioglass (BG_H0) and (b) of hydroxyapatite (HA). -----	73
Figure 4.5 (a) Transmittance FTIR spectra of bioglass/hydroxyapatite composite heated at 75	
Figure 4.6 (a) FTIR results of sintered bioglass/hydroxyapatite composite at 600°C and (b) at 1000°C after immersion in SBF (1,2,3 for BG_H20, BG_H50 and BG_H80 respectively). -----	77
Figure 4.7 (a) XRD of sintered composites at 600°C and (b) at 1000°C in SBF solution after immersion (1, 2, 3 for BG_H20, BG_H50 and BG_H80 respectively. * shows Hydroxyapatite peak).-----	79
Figure 4.8 SEM of composites sintered at 1000°C after 7 and 28 days immersion. -----	80

Figure 4.9 (a) pH changes for sintered composites at 600°C and (b) at 1000°C during immersion.-----	81
Figure 4.10 Biocompatibility of sintered composites in terms of % cell proliferation with cell line MG-63. -----	84
Figure 5.1 Thermal analysis of doped and undoped raw powder.-----	92
Figure 5.2 XRD pattern of (i) baghdadite (ii) zinc oxide doped baghdadite (iii) ZnO peaks in at 2θ of 31.4° in doped baghdadite samples. -----	93
Figure 5.3 Transmittance FTIR of baghdadite composite. -----	94
Figure 5.4 SEM with elemental mapping of prepared CaZn0 sample sintered at 800°C. ----	95
Figure 5.5 SEM with elemental mapping of prepared CaZn0.1 sample sintered at 800 °C. -	96
Figure 5.6 SEM with elemental mapping of CaZn0.25 sample sintered at 800°C.-----	97
Figure 5.7 SEM with elemental mapping of prepared CaZn0.5 sample sintered at 800°C. --	98
Figure 5.8 XRD pattern of composites after immersion in SBF for different time interval.	100
Figure 5.9 FTIR of composites after immersion in SBF for different time interval (P indicate the phosphorus peak)-----	101
Figure 5.10 SEM with elemental mapping of CaZn0 sample after 28 days of immersion in SBF. -----	102
Figure 5.11 SEM with elemental mapping of CaZn0.1 sample after 28 days of immersion in SBF. -----	103
Figure 5.12 SEM with elemental mapping of CaZn0.25 sample after 28 days of immersion in SBF. -----	104
Figure 5.13 SEM with elemental mapping of CaZn0.5 sample after 28 days of immersion in SBF. -----	105
Figure 5.14 Variation in pH in SBF.-----	106
Figure 5.15 Weight loss in sample after immersion in SBF.-----	107
Figure 5.16 Water absorption in SBF. -----	108
Figure 5.17 Bulk density with sintering temperature.-----	108
Figure 5.18 Compressive strength of samples after sintering at 800 °C. Data were presented in their average value.-----	109
Figure 5.19 Hemocompatibility of baghdadite and zinc oxide doped baghdadite (a) histograms, The “a”, “b”, and “c” letters show the significant difference with respect to CaZn0, CaZn0.1 and CaZn0.25. (b) Microcentrifuge tubes (i) positive control, (ii) CaZn0, (iii) CaZn0.1, (iv) CaZn0.25, and (v) CaZn0.5, and (c) micrograph images of samples treated with ACD blood.-----	110

Figure 5.20 Apoptosis of cells following treatment with fixed concentration of (i) CaZn0, (ii) CaZn0.1, (iii) CaZn0.25, and (iv) CaZn0.5. The treated cells were stained with DAPI. Blue color staining with DAPI suggests the living and healthy cells. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)-----	111
Figure 5.21 Shows the viability of S.aureus and E.coli on samples. Data were presented in mean \pm SD (n = 3). Letters “a” and “b” present the statistical difference (p value < 0.05) among all samples with respect to control and CaZn0 respectively. -----	113
Figure 6.1 XRD pattern of substituted bioglass and zinc oxide composites.-----	121
Figure 6.2 FTIR of substituted bioglass and zinc oxide composites. -----	121
Figure 6.3 Variation of pH of the SBF solution containing composite samples with different time intervals. -----	122
Figure 6.4 Transmittance FTIR spectra of bioglass zinc oxide composites after 7 days immersion in SBF.-----	123
Figure 6.5 Biocompatibility of composites in terms of % cell viability on MG-63cells. ---	124
Figure 7.1 XRD pattern of composites. -----	133
Figure 7.2 XRD pattern of composites after 7 days immersion in SBF.-----	134
Figure 7.3 pH value of composites after immersion in SBF. -----	135

List of Tables

Table 1.1 Uses of Biomaterials in Organs (Parida et al., 2012).	5
Table 1.2 present the application of biomaterials in different field of medical industries (Parida et al., 2012).	5
Table 1.3 Various factors of importance in material selection for biomedical applications (Ramakrishna et al., 2001)	6
Table 1.4 Classification basis for biomaterials.	8
Table 1.5 Summarized the different responses produced due to biomaterial type and tissue interaction (Rezaie et al., 2015).	9
Table 2.1 Methods for the preparation of HA (Sadat-Shojai et al., 2013) (Szcześ et al., 2017).	28
Table 2.2 Present the ZnO ceramic processing, properties, and biomedical applications (Su et al., 2019).	35
Table 3.1 Chemistry of the glass used within this work in mol%	42
Table 3.2 Bioactive glass hydroxyapatite composite system.	44
Table 3.3 Baghdadite Zinc Oxide composite system.	45
Table 3.4 Bioactive glass Zinc Oxide composite system	45
Table 3.5 Bioactive glass baghdadite composite system	45
Table 4.1 Composition of bioglass/hydroxyapatite composite.	67
Table 4.2 Phase developed after the sintering process	72
Table 4.3 Density and compressive strength of the sintered composite sample.	82
Table 5.1 Sample code with zinc oxide amount.	88
Table 6.1 Composition of zirconia substituted bioglass and Zinc oxide composite.	119